| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
ASCVD Risk Panel with Score
Test Code92053
CPT Codes
82465, 83718, 84478
Includes
Cholesterol, Total; HDL Cholesterol; Triglycerides; Non-HDL and Calculated Components; Cholesterol, Direct LDL; ASCVD Risk Scores
If Triglyceride is >400 mg/dL, Direct LDL will be performed at an additional charge (CPT code(s): 83721).
If Triglyceride is >400 mg/dL, Direct LDL will be performed at an additional charge (CPT code(s): 83721).
Preferred Specimen
2 mL serum
Patient Preparation
If a cholesterol measurement is to be performed along with triglycerides, the patient should be fasting 9-12 hours prior to collection.
The assay manufacturer Beckman Coulter advises: "N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been determined to interfere with assays for cholesterol, uric acid" where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hrs and a third dose of 100 mg/kg administered over 16 hrs.
Minimum Volume
1 mL
Other Acceptable Specimens
Plasma collected in a sodium heparin (green-top) or lithium heparin (green-top) tube
Instructions
See individual assays.
For risk calculations to be performed, the following patient specific information have to be provided at time of order:
Age: Years
Gender: M (for male) or F (for female)
Race-African American: Y (for yes) or N (for no)
Systolic Blood Pressure: mmHg
Treatment for High Blood Pressure: Y (for yes) or N (for no)
Diabetes Status: Y (for yes) or N (for no)
Smoking Status: Y (for Yes) or N (for no)
For risk calculations to be performed, the following patient specific information have to be provided at time of order:
Age: Years
Gender: M (for male) or F (for female)
Race-African American: Y (for yes) or N (for no)
Systolic Blood Pressure: mmHg
Treatment for High Blood Pressure: Y (for yes) or N (for no)
Diabetes Status: Y (for yes) or N (for no)
Smoking Status: Y (for Yes) or N (for no)
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 48 hours
Refrigerated: 7 days
Frozen: 28 days
Refrigerated: 7 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Moderate to gross icterus • Anticoagulants other than heparin
Methodology
Enzymatic • Spectrophotometry (SP)
Setup Schedule
Set up: Mon-Fri; Report available: 3-6 days
Clinical Significance
This panel provides the 10-year and lifetime risk of atherosclerotic cardiovascular disease (ASCVD) using lipid results with anthropomorphic data and family history.
The ASCVD risk assessment is recommended in the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.
The ASCVD risk assessment is recommended in the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.
